2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer. (September 2015) - Petrylak, D.; Quinn, D.; Dreicer, R.; Antonarakis, E.; Shore, N.; Corman, J.; Concepcion, R.; Pieczonka, C.; Chang, N.; DeVries, T.; Sheikh, N.; Drake, C.